Clinical Trials on Follicular Lymphoma (FL)

Total 9706 results

Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab

Lymphoma
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S8809-S9800-S9911TM- Biological Markers in Patients With Follicular Lymphoma Treated on Clinical Trial SWOG-8809, SWOG-9800, or SWOG-9911

Lymphoma
Boehringer Ingelheim

Terminated

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Lymphoma, Non-Hodgkin

Austria, Belgium, United States, Bulgaria, Croatia, Czech Republic
GlaxoSmithKline

Withdrawn

Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma

Lymphoma, Follicular

United States
GlaxoSmithKline

Completed

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients (MUNIN)

Lymphoma, Follicular

United States
Janssen-Cilag G.m.b.H

Terminated

An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma

Lymphoma, Follicular

Germany
Commissie Voor Klinisch Toegepast Onderzoek
European Organisation for Research and Treatment of Cancer - EORTC

Unknown

Chlorambucil Compared With Radiation Therapy in Treating Patients With Previously Untreated Stage III or Stage IV Follicular Lymphoma

Lymphoma

France, Netherlands, Belgium
Gilead Sciences

Completed

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas (DELTA)

Follicular Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Small Lymphocytic Lymphoma

United States, United Kingdom, Italy, Germany, Poland, France
Xinqiao Hospital of Chongqing
Xuzhou Medical University

Unknown

Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients (MendCART)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III/IV Adult Diffuse Large Cell Lymphoma | Stage III/IV Follicular Lymphoma | Stage III/IV Mantle Cell Lymphoma

China
Epizyme, Inc.

Enrolling by invitation

A Study to Assess the Long-term Safety of Tazemetostat (TRuST)

Advanced Solid Tumors | Mesothelioma | Synovial Sarcoma | Renal Medullary Carcinoma | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Non-Hodgkin Lymphoma (NHL) | Epitheliod Sarcoma (ES)

United States, France, United Kingdom, Poland, Australia, Belgium, Ukraine
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
Grupo Oncológico para el Tratamiento y el Estudio...

Unknown

Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.

Spain
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain
Hospices Civils de Lyon

Unknown

Constitutional Genetics in Follicular Lymphoma (CONPIL)

Follicular Lymphoma | Genetic Predisposition to Disease

France
National Cancer Institute (NCI)

Completed

Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma and other conditions

United States
Incyte Corporation

Active, not recruiting

A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Lymphoma

United States, Spain, Italy, Israel, Poland, United Kingdom, Canada, Czechia, Germany, Denmark, Australia, Hungary, Sweden
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Genentech, Inc.; Biogen

Completed

Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma

Lymphoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496

Lymphoma
Northwestern University
Robert H. Lurie Cancer Center

Terminated

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Lymphoma

United States
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

Lymphoma, Follicular

Spain, Belgium, Czechia, France, Croatia, Germany, Austria, New Zealand, Australia, Greece, Hungary, Poland, Russian Federation
Lymphoma Study Association

Completed

Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma

Lymphoma, Follicular

France, Italy
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402

Lymphoma
Hoffmann-La Roche

Completed

A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma

Lymphoma, Follicular

Hungary
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S8947-9800-9911-0016A Vitamin D Insufficiency in Determining Prognosis in Patients With Newly Diagnosed Follicular Lymphoma

Lymphoma
University of Pittsburgh
Biogen

Completed

Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

Non-Hodgkin Lymphoma

United States
Oslo University Hospital
Aarhus University Hospital; Hoffmann-La Roche

Recruiting

Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries (MERLIN)

Lymphoma, Follicular

Norway, Finland
Incyte Biosciences Japan GK

Completed

Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)

Lymphoma

Japan
SecuraBio

Withdrawn

Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701

Lymphoma

United States
Hoffmann-La Roche

Terminated

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma

Lymphoma, Follicular

Greece
Hoffmann-La Roche

Completed

A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma

Lymphoma, Follicular

Spain, Sweden, Canada, Mexico, Czech Republic, France, Switzerland, Australia, Israel, Korea, Republic of, United Kingdom, Italy, Brazil, Finland, Russian Federation, Peru, Denmark, Argentina, Poland, Ecuador, Norway, Slovakia
Gemin X

Completed

Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)

Lymphoma, Follicular

United States
M.D. Anderson Cancer Center
CureTech Ltd

Completed

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone

Lymphoma
Duke University
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

Lymphoma, Follicular

United States
Icon Genetics GmbH

Completed

Autologous Vaccine for Follicular Lymphoma

Lymphoma, Follicular

United States
GlaxoSmithKline

Completed

HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab

Lymphoma, Follicular

United Kingdom
Lymphoma Study Association

Completed

Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden

Lymphoma

France, Belgium
Nordic Nanovector
ICON Clinical Research

Completed

A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)

Follicular Lymphoma | Non-Hodgkin Lymphoma

United States, Korea, Republic of, Australia, Austria, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Singapore, Spain, Sweden, Switzerland, Turkey, United Kingdom
University of Kansas Medical Center

Completed

Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma

Non-Hodgkins Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | CD19 Positive

United States
University Hospital, Saarland

Unknown

Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy (MERIT-NHL)

Follicular Lymphoma

Germany
National Cancer Institute (NCI)

Completed

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Hoffmann-La Roche

Completed

An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice

Lymphoma, B-Cell, Lymphoma, Follicular

Germany
Biovest International

Unknown

Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma (BiovaxID)

Non-Hodgkins Lymphoma
The Lymphoma Academic Research Organisation

Completed

Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma

Follicular Lymphoma Patients (Phase IB) | Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II)

France, Belgium
Rush University Medical Center
GlaxoSmithKline; Millennium Pharmaceuticals, Inc.

Terminated

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Follicular Lymphoma

United States
University of Bologna

Completed

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy (FM+R-Z)

Follicular Lymphoma

Italy
Case Comprehensive Cancer Center

Terminated

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States

Clinical Trials on Follicular Lymphoma (FL)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations